What drives the AYA.AX stock price most?

AYA.AX stock reacts chiefly to clinical adoption and commercial contracts for Salix. Trial results, hospital wins, and regulatory updates will materially affect revenue expectations and investor sentiment.

Is AYA.AX stock profitable today?

No. Artrya reports trailing EPS **-0.19** and a negative PE of **-17.89**, showing it remains loss-making while investing heavily in R&D and growth initiatives.

What short-term price targets should I watch for AYA.AX stock?

Watch the 50-day average **A$3.82** as near-term resistance and the 200-day average **A$2.59** as support. Meyka's quarterly forecast of **A$4.36** implies about **43.42%** upside from today.

How does Meyka AI rate AYA.AX stock?

Meyka AI rates AYA.AX **63.40 / 100** (Grade B, HOLD). The grade blends benchmark, sector, growth and forecast data but is informational and not investment advice.

AU Stocks

AYA.AX Artrya Limited ASX after-hours 09 Mar 2026: A$3.04 signals AI upside

ByHuzaifa Zahoor March 9, 2026March 9, 2026

AYA.AX stock closed after-hours at A$3.04, down A$0.06 on the session but within a tight intraday range of A$2.94–A$3.19. Investors are watching Artrya Limited (ASX: AYA) for traction in its AI-powered Salix diagnostic platform and how clinical adoption will convert research spending into recurring revenue. The healthcare AI angle is the key driver for price action and near-term sentiment in Australia, where volume of 555,959.00 shares traded today shows steady retail and institutional interest.